CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The CCTG Annual Spring Meeting is only 7 weeks away!
The CCTG IND Program has launched the Early Clinical Trials Educational Series, a virtual education workshop series that offers topics of relevance and interest to early drug trial investigation.
The CCTG MY13 study receives $3,056,172 over 8 years to investigate time-limited versus continuous Daratumumab treatment for older people with multiple myeloma.
The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.
The CEC5 (ALLIANCE A221208) Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases trial has permanently closed.
Please save the date for the 2024 Annual Spring Meeting of Participants which will be held at the Chelsea Hotel from Friday, May 3 to Sunday, May, 5.
The spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
New ways to connect with CCTG have recently launched. CCTG is now on Instagram and Threads. The Threads app is built on the Instagram network and we have begun accounts on both platforms. Instagram and Threads is where we hope everyone in our Cancer research community can come together to discuss our research and support each others work. You can follow and connect directly with our accounts and we will make sure to follow you back.
Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.
